It will therefore be interesting to explore in depth the anti-proliferative effects of targeting both ERBB and ALK proteins in EML4-ALK-rearranged NSCLC with small molecule and antibody-based inhibitors to overcome adaptive drug-resistance of ALK-TKIs in NSCLC. This evidence concerns the gene EML4 and non-small cell lung carcinoma.